Lightstone Raising $200M Fund


(Reuters) – Lightstone Ventures, a firm formed by life-sciences partners at Morgenthaler Ventures and Advanced Technology Ventures, is raising a fund of at least $200 million.

The fund will focus on early-stage therapeutics, said a source, who did not want to be identified because of Securities and Exchange Commission regulations governing advertising of private funds. Those rules are currently being revised.

Last year, Morgenthaler and ATV told their investors they planned to spin off their life sciences teams and merge them, amid a challenging environment for life sciences. The partners will stay involved in the existing life-sciences and health investments at those firms, the person said, but new investments will be made from Lightstone.

Some venture capitalists see signs to be more positive about life sciences, including a handful of big acquisitions and a potentially speedier path to drug approval in some cases.

Image Credit: Shutterstock.com

Fundraising? Then you don’t want to miss EMERGING MANAGER CONNECT in NYC on Jan. 24. This event is packed with 100+ LPs managing more than $45 billion devoted to emerging managers combined. Details are here: http://bit.ly/2ed5fcM

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.